Guideline on clinical investigation of medicinal products in the treatment of hypertension

<table>
<thead>
<tr>
<th>Draft Agreed by EWP¹</th>
<th>07 April 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adoption by CHMP for release for consultation</td>
<td>22 July 2009</td>
</tr>
<tr>
<td>End of consultation (deadline for comments)</td>
<td>22 January 2010</td>
</tr>
<tr>
<td>Agreed by CG</td>
<td>04 November 2010</td>
</tr>
<tr>
<td>Adoption by CHMP</td>
<td>18 November 2010</td>
</tr>
<tr>
<td>Date for coming into effect</td>
<td>18 February 2011</td>
</tr>
</tbody>
</table>

Keywords | CHMP, EMEA, drug evaluation, drug approval guideline, hypertension, clinical evaluation, fixed dose combination, first line therapy, substitution therapy, efficacy criteria, safety aspects |

¹ If other WPs have been involved in discussions this needs to be specified.
Guideline on clinical investigation of medicinal products in the treatment of hypertension

Table of contents

Executive summary ................................................................. 3
1. Introduction (background) .................................................. 3
2. Scope ............................................................................... 3
3. Legal basis ....................................................................... 3
4. Assessment of efficacy criteria ........................................... 4
  4.1. Blood pressure ........................................................... 4
  4.2. Morbidity and mortality ............................................... 4
  4.3. Target organ damage .................................................. 4
5. Methods to assess efficacy .................................................... 4
  5.1. Blood pressure ........................................................... 4
  5.2. Target organ damage .................................................. 6
6. Selection of patients .............................................................. 7
7. Strategy design ................................................................... 7
8. Safety aspects .................................................................... 9
9. Fixed combinations ............................................................. 11
  9.1. General remarks ..........................................................11
  9.2. The clinical development of a fixed combination ............ 11
10. References ....................................................................... 17
11. Addendum ....................................................................... 17
Executive summary

This is the 3rd revision of the Guideline on clinical investigation of medicinal products in the treatment of hypertension. The main aim of the 3rd revision was to address the regulatory requirements for different indications of fixed dose combinations (first line, second line, substitution indication) in this therapeutic area more comprehensively.

1. Introduction (background)

There is a continuous increase of cardiovascular risk associated with increasing levels of blood pressure: the higher the blood pressure, the higher the risk of both stroke and coronary events. Nonfatal and fatal cardiovascular diseases - including coronary heart disease, stroke and congestive heart failure - as well as renal disease and all-cause mortality increase progressively with higher levels of both systolic blood pressure (SBP) and diastolic blood pressure (DBP). At every level of elevated DBP, risks increase in association with elevation of SBP. The elevations in SBP are more important than DBP not only for diagnosis and therapy but also for prognosis.

The dividing line between ‘normotension’ and ‘hypertension’ is arbitrary and might vary with age. The current definition is that this line is the level of blood pressure above which intervention has been shown to reduce the risk. In the otherwise healthy adult population values below 140/90 mmHg are considered within the normal range and values of 140/90 mmHg and greater in the hypertensive range.

Hypertension may be classified according to

- aetiology: essential or primary hypertension vs. secondary hypertension;
- severity: according to WHO/ISH, JNC 7 or ESC/ESH guidelines;
- type: systolic, diastolic or both;
- effects of treatment

2. Scope

Guidance is provided on the design of clinical studies considered to be of relevance for the evaluation of antihypertensive drugs. The current revision concerns fixed combinations in therapeutic doses for first line therapy. The guideline revision acknowledges the increasing use of fixed drug combinations in the treatment of hypertension. Recent treatment guidelines, issued by scientific societies, address the fact that certain, more severely ill hypertensive patients, could be treated with more than one drug from the start of therapy.

3. Legal basis

This guideline has to be read in conjunction with the introduction and general principles of the Annex I to Directive 2001/83 as amended.

Pertinent elements outlined in current and future EU and ICH guidelines, should also be taken into account, especially those listed in section 10 (References).
4. Assessment of efficacy criteria

4.1. Blood pressure

The goal of treating hypertension is to prevent morbidity and mortality associated with high blood pressure. Reduction in blood pressure has usually been accepted as a valid surrogate endpoint in order to assess whether this goal can be achieved by an antihypertensive agent. Notwithstanding, even if an antihypertensive effect has been proven, a new antihypertensive agent is only acceptable for registration when there is no suspicion of a detrimental effect on mortality and cardiovascular morbidity (see 5.3 and 8.9).

4.2. Morbidity and mortality

Positive effects on mortality and cardiovascular morbidity can only be evaluated properly in large-scale and long-term controlled clinical trials. Until the results are available, it should be specifically mentioned in the SPC that beneficial effects on mortality and cardiovascular morbidity are unknown.

4.3. Target organ damage

Although the prognostic relevance of target organ damage of heart, brain, eyes, kidneys and blood vessels has not yet been fully evaluated in valid clinical studies, target organ damage is presumably and plausibly associated with morbidity and mortality; this holds particularly true for left ventricular hypertrophy and proteinuria/microalbuminuria. Trials on outcomes of antihypertensive therapy, monitoring progression and regression of organ damage may provide relevant information on the comparative effectiveness of a new antihypertensive agent, but the prognostic value of drug effects with regard to morbidity and mortality (all cause or CV) remains to be established. Thus, these endpoints are considered of supportive value. Specific studies are only mandatory when specific claims are made or when there are suspicions of a detrimental effect.

5. Methods to assess efficacy

5.1. Blood pressure

Blood pressure lowering effects of anti-hypertensive therapy should be documented as the pre-/post-treatment reduction of blood pressure. Systolic blood pressure (SBP) is the preferred efficacy variable whilst diastolic blood pressure (DBP) is a mandatory secondary end point. Other secondary endpoint effects on response criteria can also be assessed. Arbitrarily, response criteria for antihypertensive therapy include the percentage of patients with a normalisation of blood pressure (reduction SBP <140 mmHg and DBP <90 mmHg) and/or reduction of SBP ≥20 mmHg and/or DBP ≥10 mmHg. Results obtained should be discussed in terms of statistical significance and in relation to their clinical relevance. Blood pressure should be measured frequently with emphasis on the maximum and minimum effects of the drug, i.e. before the next dose is given (peak-trough ratio).
The main endpoint should be blood pressure at trough which is defined as the residual effect at the end of the dose interval. The peak effect is the maximum blood pressure reduction (at steady state) identified in each patient following repeated blood pressure measurements across a dose interval. All measurements should be performed under standardised conditions and with the patient sitting in the office, at the same time of day when repeated measures are performed and ambient room temperature should be as similar as possible. Assessment of trough-peak ratio has to take into account methodological issues and a minimum value should be pre-specified (e.g. 50%) for the recommended dose range. The following methods are available:

ad a) Sphygmomanometry
Measurements with a calibrated sphygmomanometer are the standard. If not available, another device may be used which is calibrated carefully in proportion to a mercury sphygmomanometer. Use of aneroid manometer is not recommended. Appropriate cuff size must be used to ensure accurate measurement. Both SBP and DBP should be recorded. The disappearance of sound (Korotkov phase V) should be used for the diastolic reading. Two or more readings separated by 2 minutes should be averaged. If the first two readings of SBP differ by more than 5 mmHg, additional readings should be obtained. Blood pressure should be checked in both arms, at least once. Blood pressure should be recorded in the arm with the higher pressure; if differences greater than 20 mmHg for SBP and 10 mmHg for DBP are present on 3 consecutive readings, the patient should be excluded from the study. Blood pressure should be measured in either supine or sitting position or both. Additional measurements of standing blood pressure are of value for evaluating postural changes and the risk of postural hypotension. No shift from one position to another should be made during the study. Supine or sitting posture should be adopted for at least 5 minutes before measurement, and when standing BP is measured, the subject should be standing for at least 1 minute before measurement. Blood pressure should be measured under standardised conditions, as nearly as possible at the same time each day, on the same arm, by the same personnel, with the same apparatus. Blood pressure measurement during exercise may provide supportive evidence for efficacy.

ad b) Intra-arterial measurements
Intra-arterial measurement of blood pressure has been used in phase II studies to investigate the relation between dose, magnitude and duration of effect, to assess changes during exercise and to measure 24-hour efficacy. However, the method is complicated and the interpretation of the results is difficult since its prognostic value is not fully evaluated. Thus, intra-arterial measurement of blood pressure can be regarded as a valuable method in initial therapeutic studies. It is not considered to be widely applicable in the setting of clinical pivotal studies.

ad c) Non-invasive ambulatory blood pressure monitoring
As ambulatory blood pressure monitoring (ABPM) provides a better insight to blood pressure changes during everyday activities, ABPM is strongly recommended for the evaluation of new antihypertensive agents, although there are insufficient data to accept ABPM as the sole basis for efficacy in an approval process. The recorders used must fulfil international acknowledged validation procedures (e.g. AAM-IBHS). Repetitive investigations should be performed on a comparable (work-) day using the same equipment every time throughout the study.
Readings should be done with sufficient frequency. Time intervals should be short enough to get meaningful and reliable results at day and during night-time. The measurement intervals should be justified in the protocol. It is important that certain issues such as circadian variation, drop in night time pressure and time for highest vs. lowest pressure are assessable.

A certain minimum of readings/24 hours have to be evaluable. The number of evaluable readings must be sufficient to enable a proper assessment. It is suggested that in day-time 2 readings and during night-time 1 reading hourly may provide an appropriate database. Other approaches, if properly justified and validated, may be accepted. Readings should cover time before drug intake. Measurements within one hour and two hours after wake up, respectively, are recommended. At least 8 measurements should be included between 18 and 24 hours after drug intake. Analysis of the results could be performed in several ways, but it is recommended that mean values (± SD) for day- and night-time periods should be analysed separately. Special analysis could be performed to assess trough-to-peak ratio, early morning rise, drop in night-time pressure etc.

ad d) Automatic self (home) measurement

Self (home) measurement of blood pressure with the help of automatic devices has been advocated as an alternative approach to better characterise a patient's blood pressure level and to estimate the effect of antihypertensive treatment, also in case of treatment cessation. However, as stated for ABPM, there are insufficient data to accept self home measurement of blood pressure as the sole basis for the evaluation of efficacy in clinical studies.

Validation of the device used is necessary.

5.2. Target organ damage

Compared to ECG and chest radiography, echocardiography combines a higher sensitivity for LVH with a more precise assessment of the degree of LVH (i.e. as a continuous variable reflected by magnitude of LV mass). Tissue Doppler myocardial imaging and echo tracking events can be used to study LV diastolic function and arterial compliance. Changes in renal function can be assessed in terms of serum creatinine concentrations, 24-hour creatinine clearance and urinary protein excretion. Renal function could also be assessed by estimated glomerular filtration rate (eGFR) calculated by means of properly evaluated equations. The most objective method to assess renal blood flow and/or glomerular filtration rate is by using radio-isotopes, but this method is limited, among other reasons, by exposure to radioactivity. Clearance of PAH and inulin can be used as alternatives. Fundoscopy can provide evidence about retinal arteries, retina, and papilla. Ultrasound of the large vessels and/or angiography can provide evidence of arteriosclerotic plaques or increased vascular mass or increased intimal-medial thickness.

5.3 Morbidity and mortality

When conducting mortality and morbidity trials special emphasis should be placed on the effects in certain populations such as elderly patients and subjects with co-
morbidity e.g. diabetic patients. Patients above 75 years of age will need special attention. The evaluation of cardiovascular morbidity should especially take into account sequelae of severe organ damage (e.g. myocardial infarction, heart failure, stroke, renal insufficiency), and respective therapeutic interventions (e.g. co-medication, need for bypass surgery or PTCA). When planning an all-cause mortality study, further distinction should be made with regard to cardiovascular mortality and sudden death. Adjudication regarding causes of death and morbidity will be necessary.

6. Selection of patients

6.1 Study population

Generally, the study population will depend on etiology and the type of hypertension for which the drug is intended. Studies for the evaluation of efficacy or safety of a new antihypertensive drug are mainly performed in patients with primary or essential hypertension of mild to moderate severity with elevated systolic and diastolic blood pressure. Patients of both genders should be included in studies in a balanced way. Patients with more severe stages of hypertension also need to be evaluated in studies and the add-on design may be more appropriate. Attention should be placed on ethnic peculiarities and concomitant illnesses (e.g. diabetes mellitus, renal disease). There is a special need for data in elderly patients, including specific pharmacokinetic studies, dose-response curves and safety data. The number of subjects 75 years and older should be sufficient to assess both efficacy and safety in this group and specific attention should be paid to them. Salt intake and other non-pharmacological measures should be kept constant during the trial duration for all trials.

Patients with disorders causing secondary hypertension (e.g. phaeochromocytoma, adrenal adenoma, renal artery stenosis) and isolated systolic hypertension should be studied separately, if the indication is specifically claimed. This also refers to the treatment of hypertension in pregnancy which should also take into account the obstetrical and paediatric aspects of the problem.

7. Strategy design

Studies involving the first administration of medicinal products for hypertension to man do not differ essentially from those dealing with other cardioactive medicinal products. Patients receiving antihypertensive therapy who are to be included should be withdrawn from current existing treatment during a wash-out and a run-in period. The time needed for washout will depend on the half-life of the agent(s) used and time taken for the blood pressure to return to pre-treatment levels. The washout and run-in period will be variable but may take weeks to months. Patients with markedly elevated blood pressure readings may require a continuous underlying antihypertensive drug therapy.

Allocation of an individual patient to a study drug should only be performed if the basic blood pressure is stable. Initial elevated readings should be confirmed on at least two subsequent visits during one to several weeks. A wash-out period of at least 2, sometimes as long as 4 weeks is essential before commencing a clinical trial of a new antihypertensive agent. A prolonged run-in period is necessary not only due to pharmacodynamic effects of previous treatment(s) but also to avoid bias due
to the regression-toward-the-mean phenomenon.

7.1 Pharmacodynamics

These studies should include evaluations of tolerability, duration of action, haemodynamic parameters (e.g. stroke volume, PCWP, SVR), heart rate (e.g. Holter), neurohumoral parameters (e.g. RAA-system, sympathetic nervous system) and renal function. Further studies - depending on the mechanism of action of the drug - may include evaluations of orthostatic reactions, (intra)cardiac contractility, impulse formation and conduction, especially repolarisation (i.e., QT/QTc intervals), diastolic function, myocardial oxygen consumption, and coronary and regional blood flow. Which tests will be performed depend on the drug and its characteristics and the chosen tests should be justified by the Applicant.

7.2 Pharmacokinetics

Special studies should be performed in the elderly and, depending on route of elimination, in patients with varying degrees of renal dysfunction and/or hepatic dysfunction.

7.3 Interactions

Interaction studies can provide information which may help to define the position of the new drug in the therapeutic schemes (i.e. treatment algorithms) used in antihypertensive patients. Special attention should be devoted to potentially useful or unwanted interactions with other drugs which might be used alongside the investigational drug for combined treatment. These will be other antihypertensive agents of each of the major classes, but also other drugs which are likely to be used especially in the elderly patients. Special pharmacokinetic and pharmacodynamic interaction studies should be performed if results of clinical trials or the pharmacokinetic and pharmacodynamic properties of the drug give reason to specific interactions.

7.4 Therapeutic studies

Evaluation of efficacy

Dose-response studies should be randomised, placebo-controlled and double-blinded using at least 3 dosages to establish the clinically useful dose-range as well as the optimal dose. The dose schedule selected for pivotal studies must be justified on the basis of the results of the dose-finding studies in the target population. Dose schedules should be clearly defined for elderly patients and those with various risk factors. The results of the dose-response studies of a new antihypertensive agent should provide robust evidence of its efficacy as compared to placebo for each recommended dose. It is also essential to demonstrate the added contribution of each dose chosen.

Controlled trials with reference therapy should be performed aiming at demonstration of (at least) a similar efficacy/safety ratio of the drug under investigation in comparison to an acknowledged standard antihypertensive agent of the same and of other therapeutic classes. Placebo-controlled withdrawal phases can be introduced at the end of the study. A combination study with at least one
other standard antihypertensive agent is mandatory.

Special attention should be paid to reduction of the antihypertensive effect by time (tachyphylaxis).

Careful consideration should be given to the results in those patients who fail to complete the study per protocol (e.g. drop-outs due to adverse events or lack of efficacy).

Patients

The efficacy studies should include patients reflecting the target population. Generally these will mainly include patients with mild to moderate essential hypertension, but a certain proportion of patients with (very) severe hypertension should be enrolled as appropriate. The sample size depends, among others, on the target variable and its variance. Subgroup analyses for gender, race, age, etc. are desirable in order to demonstrate consistency across groups. This is unlikely to lead to indications in specific subgroups when no effect is demonstrated overall.

Design and study duration

The dose-response studies should preferably be designed as parallel group studies. Following a run-in period of 2, preferably 4 weeks, the comparative studies with reference agents should be double-blind and randomised. The dose should be increased according to the dosing rules expressed in the protocol, and at each dose level the duration of treatment should be long enough to estimate the effect of the respective dose. The parallel group design using fixed doses should be applied in some studies, instead of escalating doses. The investigational drug may either be given as mono-therapy or combined with underlying therapy.

Drug therapy in the main dose-response studies should last at least 3, preferably 6 months in order to demonstrate efficacy in terms of the antihypertensive effect and each tested dose should be maintained over at least 4 weeks when more than one dose is used. Controlled studies with reference agents should last even longer up to 6 months, in order to allow a comparison with respect to adverse drug reactions as well.

8. Safety aspects

8.1 Hypotension

This may be either symptomatic or asymptomatic. Special attention should be paid to orthostasis and first-dose phenomenon, especially at initiation of therapy or at increase of dosage.

8.2 Rebound hypertension

Withdrawal phenomena, especially rebound hypertension, should be studied specifically.

8.3 Effects on cardiac rhythm

This includes specifically (tachycardiac) pro-arrhythmic effects and effects on impulse conduction. Depending on the particular pharmacodynamic properties of the
drug, heart rate, ECG and Holter monitoring should be performed at frequent
intervals throughout the study.

8.4 Pro-ischemic effects
Coronary steal effects due to coronary vasodilation, together with potential
hypotensive effects, may lead to angina pectoris and myocardial infarction. When
suspected, this needs to be studied specifically.

8.5 Effects on target organ damage
Data on blood chemistry, urine analysis and other general laboratory investigations
should be submitted. Effects of alterations in regional blood flow in other organ
systems, especially the kidney, heart and brain can be studied. Special emphasis
should be placed on renal function, electrolyte homeostasis, and LVH. Depending on
susicion of ophthalmological side effects, ophthalmological examination should be
performed throughout the study. Special emphasis should be placed on cognitive
functions and CNS-effects (dizziness, blurred vision, syncope and TIA), especially in
the elderly.

8.6 Effects on concomitant diseases
Concomitant diseases (or comorbid conditions) include diabetes mellitus, renal
impairment, ischemic heart disease, heart failure, cerebrovascular diseases and,
more rarely, peripheral arterial occlusive disease. When specific claims are made,
studies on hypertensive patients with concomitant diseases are required. From a
safety perspective, it is expected that the new agent does not have significant
adverse events or deleterious effects on other risk factors.

8.7 Effects on concomitant risk factor
As concomitant risk factors are often present at the same time, effects on glucose
and lipid metabolism should be evaluated with special attention.

8.8 Immunological reactions
Special attention should be paid to hypersensitivity reactions of the skin and other
organs (especially liver, kidney, lungs), changes in blood cells, and hepatitis.

8.9 Long-term effects on mortality and cardiovascular morbidity
Although the risk of cardiovascular morbidity and mortality is strongly associated
with the degree of hypertension, the risk of cardiovascular disease is also
determined by many other factors, which may also be affected to a different extent
by antihypertensive therapy. Results of pharmacoepidemiological studies have
raised the issue whether, despite an equal blood pressure lowering effect, the
influence of antihypertensive drug classes on (cardiovascular) morbidity and
mortality may not be alike. Even negative effects have been suggested for certain
Therefore, a sufficient cohort of patients of both sexes and all ages should be continuously exposed to the drug for at least one year even if specific claims regarding benefit on mortality/morbidity are not made. The available data on mortality and cardiovascular morbidity from the clinical trial program should be thoroughly analysed, taking also into account preclinical data and the results obtained from other drugs of the same antihypertensive class and other classes as well. A new antihypertensive agent is only acceptable for registration if there is no suspicion of a detrimental effect on cardiovascular morbidity and mortality. Otherwise, additional studies to clarify the drug effect on these parameters are mandatory.

9. Fixed combinations

9.1 General remarks

Combination therapy in hypertension is commonly applied to improve efficacy and/or safety as compared to the respective mono-therapies. Mono-substances for the treatment of hypertension are generally combined in a fixed manner if:

- the combination of the individual components is plausible since complementary modes of action exist which result in additive antihypertensive effects, or a reduction of ADRs;
- efficacy and safety of the individual components have been proven in confirmatory clinical studies;
- the individual suitable dosage ratio evaluated in confirmatory clinical trials with the free combination has corresponded with that of the fixed combination;
- the joint application of the two components has proven to be efficacious, safe and thus clinically useful.

In order to obtain a marketing authorisation for a fixed combination, it is mandatory to prove that each active component in the scheduled dosage independently contributes towards the positive evaluation of the combination drug. Concerning morbidity and mortality data the same requirements apply as to the mono-components.

9.2 The clinical development of a fixed combination

In the situation where a combination has not yet been demonstrated to be safe and efficacious, the positive benefit/risk of the joint application of the mono-components should be demonstrated by means of a study/ies with appropriate design and dose-response data. Preferably, the factorial design should be used, allowing the simultaneous comparison of various dosage combinations with their respective components and with placebo. Ascending dosages (e.g. in a range of dose equal or superior to two) of the fixed combination could be tested in patients with insufficient response.

The results of the factorial studies should be the basis for further, confirmatory, clinical trials. It is important that the clinical studies should be designed in accordance with the indication claimed and the wording of the indication must state
clearly whether the fixed combination should be given as 1) first line therapy in patients receiving previously neither of the substances, 2) second- or third-line therapy in non-responders to the mono-components, and 3) substitution therapy in patients adequately controlled with the individual products, given concurrently, but as separate tablets at the same dose level as in the combination.

9.2.1 First line therapy

In this situation the fixed combination is considered for patients receiving previously neither of the substances. The fixed combination may contain either subtherapeutic doses or therapeutic doses, depending on the clinical justification for the combination.

9.2.1.1 Subtherapeutic doses

In this possible, although uncommon, situation the (fixed) combination of two antihypertensive agents contains a dosage lower than the respective lowest approved individual dosages for antihypertensive mono-therapy. In addition to showing at least similar efficacy to the lowest approved doses of the monotherapy, the primary aim of developing a low-dose FDC is a reduction of adverse drug reactions in particular dose-dependent adverse events (taking into account the anticipated increased frequency of idiosyncratic reactions if the patient is simultaneously confronted with two antihypertensive agents new to him).

Recognising that patients with mild to moderate hypertension are normally treated with antihypertensive mono-therapy which usually will be titrated to the individually optimised dosage, in certain patients first-line therapy with a fixed low-dose combination could be considered.

The following are required as a minimum if first-line therapy is claimed for a fixed low-dose combination.

1) Demonstration that each substance has a documented contribution within the (fixed) combination:

It is necessary (but not sufficient) that the results of a valid clinical trial evaluating a fixed low-dose combination document a statistically significant and clinically relevant greater blood pressure lowering effect than placebo, whereas the difference to each component (same subtherapeutic low dose as in the fixed combination) given separately has to be at least statistically significant. In addition, the response rate on the low-dose fixed combination should exceed that on placebo by an amount which is statistically significant and clinically valuable. If these objectives are addressed by means of a factorial design which includes groups of patients on additional doses and combinations of doses, then the conclusions regarding the low dose fixed combination of interest should still be based on the pair-wise comparisons described above.

2) Demonstration of at least similar efficacy to the lowest approved doses of each monotherapy compound

It is necessary (but not sufficient) that the blood pressure lowering effect of the low dose fixed combination is better or at least similar, i.e. at least not inferior than those of the lowest approved dosage of each component. Accordingly, the inclusion of a placebo arm in this study is helpful to establish external validity of the trial and
underline these claims.

3) Indication for a reduction of (dose-dependent) adverse drug reactions by the low
dose fixed combination as compared to the components in the lowest approved
dosages:

There should be a trend towards better safety regarding the low-dose fixed
combination as compared to each component administered at the lowest approved
dosage.

9.2.1.2 Therapeutic doses

In this situation the (fixed) combination of two or more antihypertensive agents
contains a dosage in accordance with approved individual dosages for
antihypertensive mono-therapy. According to current recommendations, the primary
aim of initiating antihypertensive therapy with a FDC would be to achieve the BP
goal in a more timely fashion, which may be more convenient and simplify the
treatment regimen. In many hypertensive patients the treatment goals for blood
pressure cannot be achieved by one drug alone. This has been shown in several
large trials, especially in the group of patients with higher initial blood pressure
(≥160/100 mmHg or >20/10 mmHg above goal) or with risk factors for
cardiovascular events. Therefore, recent hypertension guidelines recommend that
initial therapy with two or more drugs may be used in these patients. In addition,
the use of multidrug combinations may produce greater BP reduction at lower
dosage of the component agents, resulting in fewer side effects. On the other hand,
a too rapid and/or too strong reduction in blood pressure may lead to orthostatic
hypotension, renal dysfunction and cerebral hypoperfusion. Last but not least, the
indiscriminate use of FDC as first line option may lead to unnecessary drug use.

Patient selection

Appropriate patient selection is the key point and it is recommended that the
Applicant thoroughly justifies that the patients considered for a first line fixed dose
combination have a low chance to be adequately treated with mono-therapy or by a
combination in sub-therapeutic doses. Furthermore, the Applicant should show that
the risk for cardiovascular events among the included patients is sufficiently high to
justify that treatment is initiated with more than one drug. The inability to reach the
preset goal is influenced by many factors such as initial blood pressure levels, target
blood pressure, concomitant diseases, target organ damage and older age.
Therefore, only patients with at least moderate or severe hypertension and/or at
high risk for cardiovascular disease are regarded to fit into the category with a high
risk for inadequate blood pressure control on mono-therapy. The Applicant should
take into account demographic peculiarities, like age and gender, and
concomitant illnesses, as indicated in section 4 of this document. In order to
properly assess the real value of the FDC as first line therapy, it is highly
recommended that the pivotal body of evidence comes from studies conducted in
naive patients fulfilling the recommendations outlined above.

Demonstration of the blood-pressure effect of the substances

Requirements for therapeutic exploratory studies will vary depending on what
substances are used in the fixed combination. The following situations are possible:

1. All substances are well known and the joint application of the two components
has proven to be efficacious, safe and thus clinically useful.
Relevant studies should be available, either as original studies or on the basis of the literature to document the benefit/risk of the combination and the doses used. In this case, in particular when the fixed dose combination is already available for the second-line indication, one therapeutic confirmatory study could be sufficient to demonstrate its benefit in terms of obtaining a more rapid and at least comparable blood pressure lowering effect compared to the dose titrating regimen.

When all substances are known and the value of the combination of the mono-components has been documented sufficiently, in particular when the FDC is already available for second-line indication, long term safety demands could be satisfied to a large extent by bibliographic data. The completed studies should, however, supply a large enough sample for safety assessments and a safety extension may be necessary. This could be performed with an open label design and/or comparative studies with other FDC.

2. One or all substances are not well known and/or the efficacy and safety of the joint application have not been established

In this case the benefit of the combination will need to be explored further, similar to the general requirements for a fixed combination, before proceeding to the therapeutic confirmatory study. This will normally include a factorial study with comparison between the mono-components and the fixed combination.

Design of the therapeutic confirmatory study

The therapeutic confirmatory study should demonstrate that the use of the FDC as initial therapy is safe and provides a more timely blood pressure control as compared to a strategy initiated with monotherapy and subsequent addition of further substances. It should be a parallel arm study to compare the antihypertensive effects of the standard regimen of initiating and titrating one agent before adding and titrating the second, with the new regimen of titrating the fixed dose combination (FDC). As the FDC (substances X and Y) will normally consist of at least two ascending dosages, the effect of the lower dose combination will be studied during the first treatment period and compared with the full dose of X and/or Y (the mono-components) at the end of this period. At the end of this period, in non-responders, dose should be doubled in the FDC arm and the second drug (X or Y, one or the other) should be added in the mono-therapy arm(s). Subsequently, all treatment arms should be studied for the second treatment period and compared at the end of this period. Dose-titration steps may be necessary in all arms to obtain the required dosages at the end of each treatment period that should be of sufficient duration to allow a reliable treatment effect. Ultimately, the number of treatment periods will depend on the number of ascending dosages of the fixed combination. A low number of patients reaching the target blood pressure on monotherapy in the add-on arm is expected in an appropriately chosen target group.

With such an approach it is expected that the mean reduction in BP and the success rate in both arms will be similar when patients have been uptitrated to the maximal target dose. Based on demonstration of non-inferiority of the blood pressure lowering effect of the FDC as compared to the second-line approach the key parameter for evaluation of efficacy is “time until achieving target blood pressure”. Such an endpoint is in accordance with the primary aim to achieve the BP goal in a more timely fashion. The clinical relevance of the time gained remains to be demonstrated for the target group of patients. Alternative approaches, if properly justified, may be acceptable, provided that the gain obtained with the FDC as initial strategy is adequately documented as stated above.
Any fixed combination for first line treatment should not raise new safety concerns other than encountered with the mono-components. Special attention should be paid on dose-dependent side effects, including “first dose hypotension” and symptoms and signs of organ damage (e.g. renal dysfunction) initially (e.g. 1-2 weeks) and after each dose step. Attention should also be paid to serum electrolyte levels. Particular caution is necessary in patients at higher risk for orthostatic hypotension for example those with diabetes mellitus, autonomic dysfunction, and elderly patients. Safety in those patients that could be successfully treated with mono-therapy but receive a FDC in a first line approach should be addressed.

9.2.2 Second- or third-line therapy

A fixed combination may be considered when response to one or more of the mono-components is insufficient. The following strategies in conducting confirmatory clinical studies are acceptable, but it is mandatory that at least one or two pivotal clinical study/-ies is/are performed in a population of patients whose blood pressure cannot be normalised with one or all of the mono-components.

Add-on therapy

Add an additional drug to non-responders to one or more drug(s), and vice versa. Dose-titration will usually be indicated. It is necessary to demonstrate a statistically significant and clinically relevant additional blood pressure reduction of the combination in patients who did not respond adequately to standard therapeutic doses of one or more of the mono-components. Current clinical practice recommendations for the treatment of high blood pressure do not recommend forcing the dose of a single antihypertensive before considering the combination of two or sometimes even three drugs. Therefore, it is not necessarily expected that the dose of the single agent is up-titrated beyond the regular maintenance dose before the second or third agent is added. In any case, the selected upper dose-titration level of each component should be adequately justified.

Furthermore, it is necessary to show that any additional safety concerns (incidence/seriousness/severity/outcome of adverse events/adverse drug reactions) do not outweigh the additional benefit of the combination.

In non-responders it is usually sufficient to show a clinically relevant and statistically significant superiority of the combination regarding the sitting systolic and diastolic blood pressure, but it would be optimal, if such a trial could show a statistically significant improvement in response rates (blood pressure <140/90 mmHg) for the fixed combination, as well.

Sufficient duration of time (consistent with the time-response course expected for each component of the combination) should be taken into account to ensure that blood pressure levels are stable before the second drug is added to the medication.

In special situations, in particular for triple combinations, an alternative study design may be appropriate.

Parallel group comparisons

A parallel comparison of the combination with the individual components using the same therapeutic doses with the demonstration of statistically significant superior efficacy of the combination and no additional safety concerns outweighing the additional benefits of the fixed combination can be supportive for the proof of efficacy. Comparison with another fixed combination may also provide supportive
In some cases (e.g. the fixed combination of two diuretics one of which is assumed to have a potassium-sparing effect) it can be mandatory to show a statistically significant and clinically relevantly superior safety while accepting a comparable efficacy. In such a case the studies should primarily aim at safety and the indication should be worded accordingly.

9.2.3 Substitution therapy

In this situation the (fixed) combination of two or more antihypertensive agents is intended for patients adequately controlled with the individual products, given concurrently, but as separate tablets at the same dose level as in the combination. The primary aim is to reduce the number of tablets the patient has to take, which may potentially enhance adherence to therapy.

Requirements

Requirements will vary depending on which substances are used in the fixed combination.

The following additional situations are possible:

1. All substances are well known and the joint application of the two or more components is already in widespread use in the proposed dosage strengths, has proven to be efficacious and safe and thus clinically useful.

This situation includes those cases where the requirements for granting a first line indication (therapeutic doses) or an add-on indication are fulfilled. Moreover, this approach may also be acceptable for combinations of drugs for which a wide therapeutic experience is available (e.g. 5 years or more), provided there is a good plausibility and that the pharmacological rationale for the use of both drugs in combination is adequately justified. Provided that the respective data are thoroughly and reliably documented, a well founded bibliographical data analysis may be helpful in reducing the amount of clinical trials to be performed. In this case comparative pharmacokinetic data are needed, demonstrating that the two components of the fixed combination do not affect each others pharmacokinetic patterns. The pivotal data are the bioequivalence study showing bioequivalence to the components in free combination with the fixed dose.

2. One or all substances is/are not well known and/or the efficacy and safety of the joint application have not been established

In this case, original clinical data on efficacy and safety for the joint application are required. In addition to the bioequivalence study comparing the drugs in free combination with the fixed dose the benefit/risk of the combination will need to be explored further, before a substitution indication can be considered. This will normally include clinical studies showing efficacy and safety of the fixed combination as well as factorial studies for the dose-response assessments. These studies should demonstrate significant additional blood pressure reduction of the combination and that the mono-components contribute to the effects. An add-on study in non-responders should be considered in when clinical use in a substitution indication may not be clearly differentiated from a second- or third line add-on use. This may be the case when the majority of patients is not already on long term combined treatment with the individual monocomponents, but will be treated de novo with
combinations containing at least one component that is not well known. Long term safety data will also be needed. Specific attention should be paid to the doses, as used in the fixed combination tablet.

10. References

- Dose-Response Information to Support Drug Registration (ICH E4)
- Statistical Principles for Clinical Trials (ICH E9)
- Choice of Control Group in Clinical Trials (ICH E10)
- The Extent of Population Exposure to Assess Clinical Safety for Drugs (ICH E1A)
- Pharmacokinetic Studies in man (3CC3A)
- Note for Guidance on the Investigation of Drug Interactions (CPMP/EWP/560/95)
- Reporting the Results of Population Pharmacokinetic Analyses (CHMP/EWP/185990/06)
- Non-clinical Development of Fixed Combinations of Medicinal Products (EMEA/CHMP/SWP/258498/2005)

11. Addendum

FIXED COMBINATION ANTIHYPERTENSIVE MEDICINAL PRODUCTS IN SECOND LINE THERAPY

The three following relevant issues were identified regarding applications for fixed combination antihypertensives in second line therapy.

1. Indication

It was concluded that, provided sufficient evidence is included in the application, the second line indication for fixed combination medicinal product mentioned under section 4.1. should read as follows:

"Treatment of essential hypertension, <medicinal product Z> fixed dose combination (X mg /Y mg) is indicated in patients whose blood pressure is not adequately controlled on X or Y alone"

2. Posology

It was agreed that in section 4.2. Posology and method of administration" the two following recommendations should be included: "Individual dose titration with the components can be recommended” and "When clinically appropriate, direct change from monotherapy to the fixed combination may be considered”.

3. Clinical trials requirements for second line indication

In the 'Note for Guidance on clinical investigation of medicinal products in the treatment of hypertension', two types of trials are discussed: trials in patients who are non-responders to the monotherapy, and trials in general population of hypertensive patients (including potential responders).

It was agreed that different trial requirements might be needed to support the three different following indications:

3.1 In order to support the indication "Treatment of essential hypertension, <medicinal product Z> fixed dose combination (X mg /Y mg) is indicated in patients
whose blood pressure is not adequately controlled on X alone”, at least one add-on trial to active treatment in non-responders to X should be carried out.

3.2 In order to support the indication "Treatment of essential hypertension, <medicinal product Z> fixed dose combination (X mg /Y mg) is indicated in patients whose blood pressure is not adequately controlled on Y alone”, at least one add-on trial to active treatment in non-responders to Y should be carried out.

3.3 In order to support the indication "Treatment of essential hypertension, <medicinal product Z> fixed dose combination (X mg /Y mg) is indicated in patients whose blood pressure is not adequately controlled on X or Y alone”, two add-on studies one in non-responders to X and one with non-responders to Y should be carried out.

In some cases where only one add-on clinical study in non-responders has been carried out, data from appropriately designed parallel group comparative studies of the combination with the individual components may support a broader indication in both categories of non-responders.